Esthetic Wellness Med Spa
160 West Sandy Lake Road ยท Coppell, TX 75019
5.0(47 Google reviews ยท 9 in past year)
TelehealthAccepts insurance3 reviews mention GLP-1
Listing updated Oct 2, 2026
๐ฅ๐ฒ๐ป๐ฒ๐ ๐๐ฎ๐๐ ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ฎ๐น ๐ช๐ฒ๐ถ๐ด๐ต๐ ๐๐ผ๐๐
๐ฅ๐ฒ๐ป๐ฒ๐ ๐๐ฎ๐๐ ๐ ๐ฒ๐ฑ๐ถ๐ฐ๐ฎ๐น ๐ช๐ฒ๐ถ๐ด๐ต๐ ๐๐ผ๐๐ ยท 809 South MacArthur Boulevard ยท Coppell, TX 75019
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed โ RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
Care described on the practice's website
- Medically supervised weight loss
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | Yes |
| Cash pay accepted | โ |
| Accepts insurance โ per practice website | Yes |
| Accepting new patients โ per practice website | Yes |
"Not listed" means we didn't find this stated on the practice's public pages โ it doesn't mean no. โ means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Nearby providers in Coppell
Forum Health Coppell Integrative Medicine Clinic
705 West Main Street ยท Coppell, TX 75019
4.5(209 Google reviews ยท 100 in past year)
TelehealthAccepts insuranceSemaglutide today
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete ยท Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned โ Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly โ What to know about retatrutide ยท Lilly โ TRIUMPH-2/TRIUMPH-3 results ยท BioPharma Dive โ FDA submission plans ยท STAT โ Lilly expanded access (Aug 3, 2026) ยท FDA โ Concerns with unapproved GLP-1 drugs